Rapport Therapeutics, Inc.
RAPP · Nasdaq · United States
Share price · RAPP
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when RAPP's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 28 Oct 2026-18.3%
Nothing announced by RAPP that day or the session before.
- 21 Oct 2026-14.7%
- 23 Sep 2026-17.7%
Nothing announced by RAPP that day or the session before.
- 6 Aug 2026+9.2%
- 12 Jun 2026+9.1%
Nothing announced by RAPP that day or the session before.
- 7 May 2026+7.7%
- 20 Apr 2026-6.5%
Nothing announced by RAPP that day or the session before.
- 16 Apr 2026+7.7%
Nothing announced by RAPP that day or the session before.
- 2 Apr 2026+6.0%
Nothing announced by RAPP that day or the session before.
- 31 Mar 2026+13.0%
Nothing announced by RAPP that day or the session before.
Share of unusual movement by asset
For each asset, the share of RAPP's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
Assets
(1 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 3 | AMPA receptor (TARP γ8-dependent)Small molecule | Epilepsy Focal Onset Seizures |
Upcoming events
(3 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2028 (1)
Regulatory and conference events
(2)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
Quarterly & interim (11)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | $0 | $34M | $75M+ $320M short-term inv. | $40M-$42M operating cash flow | report ↗ |
View 10 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | $0 | $51M | $64M+ $372M short-term inv. | $57M-$41M operating cash flow | report ↗ |
| 2026-Q1 | $20M | $33M | $78M+ $399M short-term inv. | $20M-$13M operating cash flow | report ↗ |
| 2025-Q3 | — | $22M | $251M+ $262M short-term inv. | $27M-$17M operating cash flow | report ↗ |
| 2025-Q2 | $0 | $23M | $55M+ $205M short-term inv. | $27M-$25M operating cash flow | report ↗ |
| 2025-Q1 | $0 | $20M | $58M+ $228M short-term inv. | $24M-$20M operating cash flow | report ↗ |
| 2024-Q3 | — | $16M | $39M+ $281M short-term inv. | $18M-$16M operating cash flow | report ↗ |
| 2024-Q2 | — | $16M | $110M+ $226M short-term inv. | $18M-$16M operating cash flow | report ↗ |
| 2024-Q1 | — | $13M | $74M | $23M-$18M operating cash flow | report ↗ |
| 2023-Q3 | — | $7.6M | $159M | $8.7M-$5.4M operating cash flow | report ↗ |
| 2023-Q2 | — | $4.7M | $80M | $6.4M | report ↗ |
Annual history (3 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | — | $95M | $53M+ $438M short-term inv. | $28M-$87M operating cash flow | report ↗ |
Rapport Therapeutics reported full-year 2025 results with revenue not disclosed. R&D spend was $94.8M, up 55.5% YoY, and the company posted a net loss of $111.5M for 2025 versus $78.3M in 2024, including a Q4 net loss of $33.8M. The company ended the period with $490.5M in cash, cash equivalents, and short-term investments, excluding restricted cash, which it expects to fund operations into the second half of 2029.
RAP-219's Phase 2a trial in focal onset seizures met its primary endpoints, with a 77.8% median reduction in clinical seizure frequency; the Phase 3 program in FOS is expected to begin in Q2 2026, with a Phase 3 trial in primary generalized tonic-clonic seizures planned for the first half of 2027. Topline results from the Phase 2 bipolar mania trial are expected in the first half of 2027, the FDA lifted the clinical hold on the diabetic peripheral neuropathic pain program with further investment deferred, and the company entered a collaboration with Tenacia Biotechnology for RAP-219 in Greater China, with a $20M upfront payment and up to approximately $308M in potential milestones plus tiered royalties. IND-enabling activities are also underway for a long-acting injectable formulation and the α6β4 program.
Insider transactions
Open-market activity, trailing 12 months: 11 purchases ($22.0M), 66 sales ($46.7M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-10-30 | Third Rock Ventures V, L.P.; Third Rock Ventures GP V, LP; TRV GP V, LLC; Third Rock Ventures VI, L.P.; Third Rock Ventures GP VI, L.P.; TRV GP VI, LLC · director, 10% owner; director, 10% owner; director, 10% owner; director, 10% owner; director, 10% owner; director, 10% owner | Award / grant | 238,095 | $21.00 | $5.0M | Form 4 |
| 2026-10-30 | Third Rock Ventures V, L.P.; Third Rock Ventures GP V, LP; TRV GP V, LLC; Third Rock Ventures VI, L.P.; Third Rock Ventures GP VI, L.P.; TRV GP VI, LLC · director, 10% owner; director, 10% owner; director, 10% owner; director, 10% owner; director, 10% owner; director, 10% owner | Award / grant | 1,190,476 | $21.00 | $25.0M | Form 4 |
| 2026-10-28 | HEALY JAMES · director | Open-market purchase | 952,380 | $21.00 | $20.0M | Form 4 |
| 2026-10-28 | HEALY JAMES · director | Open-market purchase | 6,395 | $21.00 | $134K | Form 4 |
| 2026-10-28 | HEALY JAMES · director | Open-market purchase | 3,772 | $21.00 | $79K | Form 4 |
| 2026-10-28 | HEALY JAMES · director | Open-market purchase | 6,933 | $21.00 | $146K | Form 4 |
| 2026-10-23 | Sanchez Ramiro · director | Open-market purchase | 3,600 | $27.35 | $98K | Form 4 |
| 2026-10-22 | MARAGANORE JOHN · director | Open-market purchase | 8,239 | $26.38 | $217K | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 147 reporting institutions held 52.5M shares ($1.6B, 88.5% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | FMR LLC | 7,168,939 | $224.3M |
| 2 | TRV GP V, LLC | 7,135,233 | $223.3M |
| 3 | ARCH Venture Management, LLC | 3,728,738 | $116.7M |
| 4 | Capital International Investors | 3,097,973 | $96.9M |
| 5 | Cormorant Asset Management, LP | 2,957,521 | $92.5M |
| 6 | GOLDMAN SACHS GROUP INC | 2,942,251 | $92.1M |
| 7 | BlackRock, Inc. | 2,505,955 | $78.4M |
| 8 | Sofinnova Investments, Inc. | 1,904,408 | $59.6M |
| 9 | JOHNSON & JOHNSON | 1,784,517 | $55.8M |
| 10 | Polar Capital Holdings Plc | 1,642,461 | $51.4M |
| 11 | BAKER BROS. ADVISORS LP | 1,547,090 | $48.4M |
| 12 | Vestal Point Capital, LP | 1,436,229 | $44.9M |
| 13 | VANGUARD CAPITAL MANAGEMENT LLC | 1,325,082 | $41.5M |
| 14 | TRV GP VI, LLC | 969,218 | $30.3M |
| 15 | UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 918,866 | $28.8M |